BAC
NYMX

Boys Arnold & Co’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Boys Arnold & Co’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-13,000
Closed -$5K – 219
2014
Q4 		$5K Buy
+13,000
New +$27.7K ﹤0.01% 203

Other funds holding NYMX

AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Boys Arnold & Co's NYMX Position: Q1 2015 in Review

Boys Arnold & Co sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2015, closing a stake of 13,000 shares — an estimated $5K sold.

Boys Arnold & Co first reported a position in NYMX in Q4 2014 and held it in 1 quarter. The position peaked at $5K in Q4 2014. 21 funds tracked by Wall St. Rank hold NYMX as of Q1 2015.

  • Boys Arnold & Co reported no remaining Nymox Pharmaceutical Corp position as of Q1 2015 after selling out during the quarter.
  • Boys Arnold & Co sold 13,000 Nymox Pharmaceutical Corp shares in Q1 2015, an estimated $5K.
  • Boys Arnold & Co first reported a position in Nymox Pharmaceutical Corp in Q4 2014 and held it in 1 quarter.
  • Boys Arnold & Co's Nymox Pharmaceutical Corp position peaked at $5K in Q4 2014.
  • 21 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2015.

Based on Boys Arnold & Co's 13F filing for Q1 2015, filed 22 Apr 2015.